{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T10:10:09Z","timestamp":1765879809847,"version":"3.48.0"},"reference-count":47,"publisher":"BMJ","issue":"9","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2019,8,16]]},"published-print":{"date-parts":[[2019,9]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Chronic Myeloid Leukaemia (CML) constitutes 15% of new adult leukaemia cases as well as 2%\u20133% of leukaemia in children under 15% and 9% of leukaemias in adolescents 15\u201319 years of age annually. The introduction of Tyrosine Kinase Inhibitors (TKI) therapy has dramatically improved survival in these patients, yet the off-target effects of this treatment may have long-term health impacts on CML survivors. The risk of adverse health outcomes is especially important in children, where TKI exposure may occur during critical windows of growth and puberty, and patients require treatment for prolonged periods of time. The aim of this systematic review protocol is to report on the methods used to conduct a systematic review to investigate the endometabolic and bone health effects of TKI therapy in CML.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>Searches will be conducted in the Cochrane Central Register of Controlled Trials, EMBASE and MEDLINE from inception on August 1st, 2019. Searches may be updated while performing the systematic review to ensure new evidence is included if applicable. Grey literature search will include ClinicalTrials.gov and ProQuest Dissertations and Theses A&amp;I. We will perform a meta-analysis if there are at least two studies reporting similar populations, interventions, methods and tracking the same outcome measures. The studies should also have similar age and sex distributions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>As this is a systematic review protocol, it does not include patient data; therefore, Research Ethics Board approval is not indicated. The systematic review will be published in a peer-reviewed journal and presented at international conferences.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PROSPERO registration number<\/jats:title>\n                    <jats:p>CRD42018091175.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2019-030092","type":"journal-article","created":{"date-parts":[[2019,9,11]],"date-time":"2019-09-11T08:55:19Z","timestamp":1568192119000},"page":"e030092","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Evaluating the endometabolic and bone health effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukaemia: a systematic review protocol"],"prefix":"10.1136","volume":"9","author":[{"given":"Janatani","family":"Balakumaran","sequence":"first","affiliation":[{"name":"Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada"},{"name":"Division of Pediatric Endocrinology, McMaster University, Hamilton, Ontario, Canada"},{"name":"Michael G. De Groote School of Medicine, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanisha","family":"Birk","sequence":"additional","affiliation":[{"name":"Michael G. De Groote School of Medicine, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Breanne","family":"Golemiec","sequence":"additional","affiliation":[{"name":"Michael G. De Groote School of Medicine, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wryan","family":"Helmeczi","sequence":"additional","affiliation":[{"name":"Michael G. De Groote School of Medicine, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeyanth","family":"Inkaran","sequence":"additional","affiliation":[{"name":"Michael G. De Groote School of Medicine, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun-ya","family":"Kao","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Leigh","sequence":"additional","affiliation":[{"name":"Michael G. De Groote School of Medicine, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Saliba","sequence":"additional","affiliation":[{"name":"Michael G. De Groote School of Medicine, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rishi","family":"Sharma","sequence":"additional","affiliation":[{"name":"Michael G. De Groote School of Medicine, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Spatafora","sequence":"additional","affiliation":[{"name":"Michael G. De Groote School of Medicine, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristin","family":"Wright","sequence":"additional","affiliation":[{"name":"Michael G. De Groote School of Medicine, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Yao","sequence":"additional","affiliation":[{"name":"Michael G. De Groote School of Medicine, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Hillis","sequence":"additional","affiliation":[{"name":"Division of Hematology Oncology, Juravinski Cancer Center, Hamilton, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Banfield","sequence":"additional","affiliation":[{"name":"Health Sciences Library, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lehana","family":"Thabane","sequence":"additional","affiliation":[{"name":"Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada"},{"name":"Department of Anesthesia, McMaster University, Hamilton, Ontario, Canada"},{"name":"Centre for Evaluation of Medicines, McMaster University, Hamilton, Ontario, Canada"},{"name":"Biostatistics Unit, St Joseph's Healthcare-Hamilton, Hamilton, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uma","family":"Athale","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada"},{"name":"Division of Hematology Oncology, McMaster Children's Hospital, Hamilton, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6403-4715","authenticated-orcid":false,"given":"M Constantine","family":"Samaan","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada"},{"name":"Division of Pediatric Endocrinology, McMaster University, Hamilton, Ontario, Canada"},{"name":"Michael G. De Groote School of Medicine, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2019,9,11]]},"reference":[{"key":"2025121602053487000_9.9.e030092.1","unstructured":"Smith MA , Ries LAG , Gurney JG , et al . Leukemia. In: Ries LAG , Smith MA , Gurney JG , et al , eds. Cancer incidence and survival among children and adolescents: United States seer program 1975-1995. Bethesda: MD: National Cancer Institute, SEER Program, 1999."},{"key":"2025121602053487000_9.9.e030092.2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21551"},{"key":"2025121602053487000_9.9.e030092.3","unstructured":"Howlader N , Noone A , Krapcho M . Seer cancer statistics review (Csr) 1975-2016. Bethesda: MD: National Cancer Institute, 2019. https:\/\/seer.cancer.gov\/csr\/1975_2016\/"},{"key":"2025121602053487000_9.9.e030092.4","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/S0140-6736(13)62120-0","article-title":"Chronic myeloid leukaemia","volume":"385","author":"Apperley","year":"2015","journal-title":"The Lancet"},{"key":"2025121602053487000_9.9.e030092.5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-02-005686"},{"key":"2025121602053487000_9.9.e030092.6","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26679"},{"key":"2025121602053487000_9.9.e030092.7","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/91.2.163"},{"key":"2025121602053487000_9.9.e030092.8","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00277-015-2325-z","article-title":"Natural course and biology of CML","volume":"94","author":"Chereda","year":"2015","journal-title":"Ann Hematol"},{"key":"2025121602053487000_9.9.e030092.9","doi-asserted-by":"publisher","DOI":"10.1038\/nm0596-561"},{"key":"2025121602053487000_9.9.e030092.10","doi-asserted-by":"publisher","DOI":"10.1038\/nrm1280"},{"key":"2025121602053487000_9.9.e030092.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062867"},{"key":"2025121602053487000_9.9.e030092.12","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.355"},{"key":"2025121602053487000_9.9.e030092.13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-09-047266"},{"key":"2025121602053487000_9.9.e030092.14","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.38"},{"key":"2025121602053487000_9.9.e030092.15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-04-083196"},{"key":"2025121602053487000_9.9.e030092.16","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.011452"},{"key":"2025121602053487000_9.9.e030092.17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055229"},{"key":"2025121602053487000_9.9.e030092.18","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1615\/CritRevOncog.v17.i1.30","article-title":"Therapeutic targeting of Bcr-Abl: prognostic markers of response and resistance mechanism in chronic myeloid leukaemia","volume":"17","author":"Yeung","year":"2012","journal-title":"Crit Rev Oncog"},{"key":"2025121602053487000_9.9.e030092.19","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.5"},{"key":"2025121602053487000_9.9.e030092.20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002315"},{"key":"2025121602053487000_9.9.e030092.21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0912614"},{"key":"2025121602053487000_9.9.e030092.22","doi-asserted-by":"crossref","unstructured":"Wei G , Rafiyath S , Liu D . First-Line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib. J Hematol Oncol 2010;3.doi:10.1186\/1756-8722-3-47","DOI":"10.1186\/1756-8722-3-47"},{"key":"2025121602053487000_9.9.e030092.23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1205127"},{"key":"2025121602053487000_9.9.e030092.24","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-0258"},{"key":"2025121602053487000_9.9.e030092.25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-390120"},{"key":"2025121602053487000_9.9.e030092.26","doi-asserted-by":"publisher","DOI":"10.1038\/nrm.2017.89"},{"key":"2025121602053487000_9.9.e030092.27","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-07-102061"},{"key":"2025121602053487000_9.9.e030092.28","doi-asserted-by":"crossref","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Syst Rev"},{"key":"2025121602053487000_9.9.e030092.29","doi-asserted-by":"crossref","DOI":"10.1186\/s13643-016-0191-y","article-title":"Implementing PRISMA-P: recommendations for prospective authors","volume":"5","author":"Moher","year":"2016","journal-title":"Syst Rev"},{"key":"2025121602053487000_9.9.e030092.30","unstructured":"Reeves BC , Deeks JJ , Higgins JPT , et al . Chapter 13: Including non-randomized studies. In: Higgins JPT , Green S , eds. Cochrane Handbook for systematic reviews of intervneions version 5.1.0. (updated March 2011): the Cochrane collaboration 2011, 2011. www.handbook.cochrane.org"},{"key":"2025121602053487000_9.9.e030092.31","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2337\/dc18-S002","article-title":"2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes\u20142018","volume":"41","year":"2018","journal-title":"Diabetes Care"},{"key":"2025121602053487000_9.9.e030092.32","unstructured":"EndNote [program]. 7.8 version: Clarivate Analytics, 2016"},{"key":"2025121602053487000_9.9.e030092.33","doi-asserted-by":"crossref","unstructured":"Liberati A , Altman DG , Tetzlaff J , et al . The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009;339.doi:10.1136\/bmj.b2700","DOI":"10.1136\/bmj.b2700"},{"key":"2025121602053487000_9.9.e030092.34","unstructured":"Higgins JPT , Sterne JAC , Savovic J , et al . A revised tool for assessing risk of bias in randomized trials. In: Chandler J , McKenzie J , Boutron I , et al , eds. Cochrane methods: cochrane database of systematic reviews 2016, 2016."},{"key":"2025121602053487000_9.9.e030092.35","unstructured":"Wells GA , Shea B , O'Connell D , et al . The Newcastle-Ottawa scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses, 2009. Available: http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp"},{"key":"2025121602053487000_9.9.e030092.36","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-153-4-201008170-00263"},{"key":"2025121602053487000_9.9.e030092.37","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.328.7454.1490","article-title":"Grading quality of evidence and strength of recommendations","volume":"328","author":"Atkins","year":"2004","journal-title":"BMJ"},{"key":"2025121602053487000_9.9.e030092.38","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1002\/pbc.26028","article-title":"Recognizing endocrinopathies associated with tyrosine kinase inhibitor therapy in children with chronic myelogenous leukemia","volume":"63","author":"Samis","year":"2016","journal-title":"Pediatr Blood Cancer"},{"key":"2025121602053487000_9.9.e030092.39","doi-asserted-by":"crossref","DOI":"10.4084\/mjhid.2014.028","article-title":"Tyrosine kinase inhibitors and pregnancy","volume":"6","author":"Abruzzese","year":"2014","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"2025121602053487000_9.9.e030092.40","doi-asserted-by":"crossref","unstructured":"Moura MS , Benevides TCL , Delamain MT , et al . Evaluation of anemia after long-term treatment with imatinib in chronic myeloid leukemia patients in chronic phase. Hematol Transfus Cell Ther 2019.doi:10.1016\/j.htct.2019.03.006","DOI":"10.1016\/j.htct.2019.03.006"},{"key":"2025121602053487000_9.9.e030092.41","unstructured":"Deeks JJ , Higgins JPT , Altman DG . Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT , Green S , eds. Cochrane Handbook for systematic reviews of intervneions version 5.1.0. (updated March 2011): the Cochrane collaboration 2011, 2011. www.handbook.cochrane.org"},{"key":"2025121602053487000_9.9.e030092.42","unstructured":"Sterne JAC , Egger M , Moher D . Chapter 10: Addressing reporting biases. In: Higgins JPT , Green S , eds. Cochrane Handbook for systematic reviews of intervention version 5.1.0. (updated March 2011): the Cochrane collaboration 2011. www.handbook.cochrane.org."},{"key":"2025121602053487000_9.9.e030092.43","unstructured":"Review Manager . (RevMan) [program]. 5.3 version. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014."},{"key":"2025121602053487000_9.9.e030092.44","unstructured":"CMA . Comprehensive Meta-Analysis (CMA) [program]. 3 version. Englewood NJ: Biostat, 2009."},{"key":"2025121602053487000_9.9.e030092.45","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-04-347575"},{"key":"2025121602053487000_9.9.e030092.46","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.51"},{"key":"2025121602053487000_9.9.e030092.47","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-012-1630-5"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2019-030092","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T10:05:46Z","timestamp":1765879546000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2019-030092"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":47,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2019,9,11]]},"published-print":{"date-parts":[[2019,9]]}},"alternative-id":["10.1136\/bmjopen-2019-030092"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2019-030092","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"type":"print","value":"2044-6055"},{"type":"electronic","value":"2044-6055"}],"subject":[],"published":{"date-parts":[[2019,9]]}}}